Anti- XXXX efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical @entity788 models.

@entity788 @entity39 @entity5 @entity19 @entity23294 @entity3 @entity3112
UNASSIGNED: Heparin and its derivatives are known to attenuate @entity5 @entity3 in preclinical models, but have not been used clinically due to adverse bleeding effects. This study compared the efficacy of S-NACH (a sulfated non-anticoagulant heparin) versus @entity23294 (a low molecular weight heparin) in inhibiting @entity3 of a growing @entity5 and following surgical excision of @entity5 in a @entity788 @entity19 model. The efficacy of S-NACH versus @entity23294 on @entity3 of the @entity5 was evaluated in each experiment using IVIS imaging. Athymic female @entity19 were treated with S-NACH or @entity23294 , and 30  min later luciferase-transfected @entity788 cells (Mpanc96) were implanted into the spleen; treatment was continued daily until termination. Next we studied the effect of S-NACH versus @entity23294 on @entity3 after surgical excision of the @entity5 after 3 weeks of daily treatment with S-NACH or @entity23294 . S-NACH reduced surgically induced @entity3 (p<0.01) and @entity5 recurrence (p<0.05) relative to control. Histopathological studies demonstrated significant increase in @entity5 @entity39 mediated by S-NACH and to lesser extent by @entity23294 as compared to control group. Furthermore, either S-NACH or @entity23294 upregulated the expression of the junctional adhesion molecule @entity3112 in @entity788 cells where its low expression enhances @entity5 cell migration and invasion. In terms of bleeding time (BT), S-NACH did not affect BT as compared to @entity23294 , which doubled BT. These data suggest that S-NACH is an effective and safe anti-metastatic agent and warrants further clinical evaluation.
